Tessier-Lavigne Marc 4
4 · Denali Therapeutics Inc. · Filed Nov 3, 2022
Insider Transaction Report
Form 4
Tessier-Lavigne Marc
Director
Transactions
- Sale
Common Stock
2022-11-01$30.20/sh−8,748$264,190→ 1,901,608 total - Sale
Common Stock
2022-11-02$30.33/sh−11,252$341,273→ 1,890,356 total
Holdings
- 79,173(indirect: By Trust)
Common Stock
- 78,848(indirect: By Trust)
Common Stock
- 78,848(indirect: By Trust)
Common Stock
Footnotes (7)
- [F1]The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.48 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]Includes 5,986 unvested restricted stock units.
- [F4]The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.90 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F5]The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee.
- [F6]The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee.
- [F7]The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee.